Estrella Immunopharma, Inc.
For the period ended Jun 30, 2025. Filed Aug 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 12, 2025
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2025-03-31; filed 2025-05-14.
0001213900-25-043365
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of Proceeds from Registered SecuritiesDefaults Upon Senior SecuritiesMine Safety DisclosuresCurrent report: 10-Q
Period ended 2025-06-30; filed 2025-08-12.
0001213900-25-074567
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of Proceeds from Registered SecuritiesDefaults Upon Senior SecuritiesMine Safety DisclosuresThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 20 previous paragraphs and 15 current paragraphs.
13 unchanged; 1 reworded; 1 added; 6 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 2 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (1)
Current report
On August 1, 2025, we received an additional written notice from the Listing Qualifications Department of Nasdaq stating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(2) because it has not maintained a minimum Market Value of Listed Securities (“MVLS”) of $35 million for the last 30 consecutive business days, specifically from June 13, 2025, to July 31, 2025. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided a compliance period of 180 calendar days, or until January 28, 2026, to regain compliance. To regain compliance, the Company's MVLS must close at $35 million or more for a minimum of ten consecutive business days during this period.
Removed paragraphs (6)
Previous report
(a) Recent Sales of Unregistered Securities
Previous report
(b)Use of Proceeds
Previous report
(c) Purchases of Equity Securities by the Issuer and Affiliated Purchasers
Previous report
The following table provides information with respect to repurchases of our Common Stock during each month of the quarter ended March 31, 2025.
Previous report
Issuer Purchases of Common Stock**(i)**
Reworded paragraphs (1)
Previous wording
The Company intends to monitor thebid price of the Company’s listed securities and may, if appropriate, consider available options to regain compliance with the Rule. There can be no assurance that the Company will be able to regain compliance with the Rule.
Current wording
The Company intends to monitor thebid price and Market Value of the Company’s listed securities and may, if appropriate, consider available options to regain compliance with the Rule. There can be no assurance that the Company will be able to regain compliance with the Rule.